Final answer:
The statement is false; while KRAS mutations are common in pancreatic adenocarcinoma, they are not as prevalent in cholangiocellular carcinoma as the question suggests. The correct option is b) False
Step-by-step explanation:
The statement that KRAS mutation is present in 90% of pancreatic adenocarcinomas and cholangiocellular carcinomas is false. The KRAS mutation is commonly associated with pancreatic cancer, specifically pancreatic adenocarcinomas, but it is not present in such a high percentage of cholangiocellular carcinomas.
Pancreatic cancers are indeed fast-growing and can often go undetected until they are in an advanced stage, which is why early detection and effective treatments are major goals of medical research. While certain mutations like KRAS are expressed in both cancerous and healthy cells, the accumulation of mutations can lead to uncontrolled cell division observed in cancer. The correct option is b) False